1973 a multicenter, placebo-controlled trial investigating the safety and efficacy of once daily tadalafil in MEN with signs and symptoms of benign prostatic hyperplasia taking concomitant A1-adrenergic antagonist therapy
Abstract
You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical and Hormonal Therapy1 Apr 20111973 A MULTICENTER, PLACEBO-CONTROLLED TRIAL INVESTIGATING THE SAFETY AND EFFICACY OF ONCE DAILY TADALAFIL IN MEN WITH SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA TAKING CONCOMITANT A1-ADRENERGIC ANTAGONIST THERAPY Evan Goldfischer, John Kowalczyk, William Clark, Erin Brady, Michael Shane, Nancy Dgetluck, and Suzanne Klise Evan GoldfischerEvan Goldfischer Poughkeepsie, NY More articles by this author , John KowalczykJohn Kowalczyk Los Angeles, CA More articles by this author , William ClarkWilliam Clark Anchorage, AK More articles by this author , Erin BradyErin Brady Indianapolis, IN More articles by this author , Michael ShaneMichael Shane Indianapolis, IN More articles by this author , Nancy DgetluckNancy Dgetluck Basking Ridge, NJ More articles by this author , and Suzanne KliseSuzanne Klise Indianapolis, IN More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.2198AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The standard-of-care medical therapy for the treatment of moderate to severe symptoms of benign prostatic hyperplasia is alpha1-adrenergic antagonist (α-blocker)-therapy. Tadalafil is currently under investigation for the treatment of benign prostatic hyperplasia. This study investigated the safety of daily…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.